BD
Therapeutic Areas
Aptose Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Tuspetinib (HM43239) | Relapsed/Refractory AML | Phase 1/2 |
| Luxeptinib (CG-806) | Relapsed/Refractory B-cell malignancies (CLL, NHL) | Phase 1a/b |
Leadership Team at Aptose Biosciences
WG
William G. Rice, Ph.D.
Chairman of the Board, President & Chief Executive Officer
RB
Rafael Bejar, M.D., Ph.D.
Senior Vice President, Chief Medical Officer
FP
Fletcher Payne
Senior Vice President, Chief Financial Officer & Chief Business Officer
DR
Denis R. Burger, Ph.D.
Board Member, Lead Director
EM
Erich M. Platzer, M.D., Ph.D.
Board Member